Treatment with SMOi has been also shown to enhance the efficacy of EGFR inhibitors in non-small cell lung cancer (Ahmad et al., 2013), prostate cancer (Mimeault et al., 2006, 2007) and glioblastoma CSCs (Eimer et al., 2012). The gene discussed is EGFR; the disease is prostate carcinoma.